All In Biotech

Drug Trial Radar · NCT03136185

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis

Last checked: Nov 19, 2026Latest source record: Jan 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

90

Actual

Start

Jul 18, 2017

Primary completion

Mar 8, 2022

Study completion Mar 8, 2022

Sponsor

Sponsor type
Industry
First posted
May 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2 open-label study to evaluate the safety, tolerability, steady-state pharmacokinetic (PK) and pharmacodynamics (PD) of a lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat (IMG-7289/MK-3543), administered orally once daily in participants with myelofibrosis. The primary hypothesis is that bomedemstat is a safe and tolerable orally available agent when administered to participants with myelofibrosis including primary myelofibrosis (PMF), post-polycythaemia vera-myelofibrosis (PPVMF), and post-essential thrombocythaemia-myelofibrosis (PET-MF) (collectively referred to as 'MF'); inhibition of LSD1 by bomedemstat will reduce spleen size in those with splenomegaly, improve haematopoiesis and reduce constitutional symptoms associated with these disorders.

Conditions

  • Myelofibrosis
  • Post-polycythemia Vera Myelofibrosis (PPV-MF)
  • Post-essential Thrombocythemia Myelofibrosis (PET-MF)
  • Primary Myelofibrosis (PMF)

Interventions

  • BomedemstatDrug

    Oral (capsule) administration according to dose allocation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to Day 7 of the ITP
  2. Number of Participants With Serious Adverse EventsTime frame: Up to approximately 30 months
  3. Number of Participants With Adverse EventsTime frame: Up to approximately 30 months
  4. Number of Participants That Discontinued Study Treatment Due To AEsTime frame: Up to approximately 29 months
  5. Phase 1/2a Portion: Observed Maximum Concentration (Cmax) of BomedemstatTime frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
  6. Phase 1/2a Portion: Time to Maximum Concentration (Tmax) of BomedemstatTime frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
  7. Phase 1/2a Portion: Area Under the Concentration-time Curve of Bomedemstat From Time 0 to 24 Hours Post-dose (AUC0-24)Time frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
  8. Phase 1/2a Portion: Apparent Total Clearance (CL/F) of Bomedemstat After Oral AdministrationTime frame: Day 21: Pre-dose and 0.5, 1, 2, 3, 4, 8, and 24 hours (Day 22) after dosing.
  9. Percentage Change From Baseline in Spleen VolumeTime frame: Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), and ATP1 Day 168 (Study Day 337)
  10. Percentage Change From Baseline in Spleen SizeTime frame: Baseline, ITP Day 84 (Study Day 84), ITP Day 168 (Study Day 168), ATP1 Day 84 (Study Day 253), ATP1 Day 168 (Study Day 337), ATP2 Day 84 (Study Day 422), ATP2 Day 168 (Study Day 506), and ATP3 Day 84 (Study Day 591)

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan

  • Royal Adelaide Hospital

    Adelaide, South Australia, Australia

  • Universitatsklinikum Essen

    Essen, Germany

  • Azienda Ospedaliero Universitaria Careggi

    Florence, Italy

  • Guy's and St Thomas' Hospitals

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.